| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 8632- | MBZ, | Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo |
| - | vitro+vivo, | Lung, | NA |
| 8642- | MBZ, | In vitro and in vivo anticancer activity of mebendazole in colon cancer: a promising drug repositioning |
| - | vitro+vivo, | CRC, | HT-29 | - | NA, | NA, | MCF10 |
| 8655- | MBZ, | Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells |
| - | in-vitro, | Melanoma, | NA |
| 8717- | MeJa, | Methyl jasmonate induces apoptosis and pro-apoptotic autophagy via the ROS pathway in human non-small cell lung cancer |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | Calu-1 | - | in-vitro, | Lung, | H157 | - | in-vitro, | Lung, | H1792 |
| 8725- | MeJa, | Methyl jasmonate leads to necrosis and apoptosis in hepatocellular carcinoma cells via inhibition of glycolysis and represses tumor growth in mice |
| - | vitro+vivo, | HCC, | HCCLM3 | - | in-vitro, | Liver, | Bel-7402 | - | in-vitro, | Liver, | Hep3B | - | in-vitro, | HCC, | SMMC-7721 cell |
| 8718- | MeJa, | Methyl jasmonate induces apoptosis through induction of Bax/Bcl-XS and activation of caspase-3 via ROS production in A549 cells |
| - | in-vitro, | Lung, | A549 |
| 1898- | MeJa, | Methyl jasmonate and its potential in cancer therapy |
| - | Review, | Var, | NA |
| 8752- | MeSA, | Rad, | Methylseleninic Acid Induces Lipid Peroxidation and Radiation Sensitivity in Head and Neck Cancer Cells |
| - | in-vitro, | HNSCC, | CAL27 | - | in-vitro, | SCC, | SCC25 |
| 8762- | MeSA, | Methylseleninic Acid Sensitizes Ovarian Cancer Cells to T-Cell Mediated Killing by Decreasing PDL1 and VEGF Levels |
| - | in-vitro, | Ovarian, | A2780S |
| 5796- | MET, | Tumor, whole blood, plasma, and tissue concentrations of metformin in lung cancer patients |
| - | Human, | Lung, | NA |
| 5534- | MF, | Targeted Osmotic Lysis of Highly Invasive Breast Carcinomas Using Pulsed Magnetic Field Stimulation of Voltage-Gated Sodium Channels and Pharmacological Blockade of Sodium Pumps |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 5241- | MF, | A review on the use of magnetic fields and ultrasound for non-invasive cancer treatment |
| - | Review, | Var, | NA |
| 2244- | MF, | Little strokes fell big oaks: The use of weak magnetic fields and reactive oxygen species to fight cancer |
| - | Review, | Var, | NA |
| 2237- | MF, | The Effect of Pulsed Electromagnetic Field Stimulation of Live Cells on Intracellular Ca2+ Dynamics Changes Notably Involving Ion Channels |
| - | in-vitro, | AML, | KG-1 | - | in-vitro, | Nor, | HUVECs |
| 2261- | MF, | Tumor-specific inhibition with magnetic field |
| - | in-vitro, | Nor, | GP-293 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Lung, | A549 |
| 2260- | MF, | Alternative magnetic field exposure suppresses tumor growth via metabolic reprogramming |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | LN229 | - | in-vivo, | NA, | NA |
| 8483- | MF, | Magnetic Fields in Cancer Therapy: Mechanistic Insights, Signaling Pathways, and Evidence from Clinical and In Vitro Studies |
| - | Review, | Var, | NA |
| 8489- | MF, | Pulsed electromagnetic fields induce ferroptosis in osteosarcoma cells and promote osteogenic differentiation |
| - | in-vitro, | OS, | U2OS | - | in-vitro, | OS, | MG63 |
| 8485- | MF, | doxoR, | Static magnetic field promotes the doxorubicin toxicity effects on osteosarcoma cells |
| - | in-vitro, | OS, | G292 |
| 4092- | MF, | Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology |
| - | Review, | Var, | NA |
| 3465- | MF, | Magnetic fields and angiogenesis |
| - | Review, | Var, | NA |
| 3478- | MF, | One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study |
| - | Trial, | BC, | NA | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | C2C12 |
| 3480- | MF, | Cellular and Molecular Effects of Magnetic Fields |
| - | Review, | Nor, | NA |
| 4354- | MF, | doxoR, | Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach |
| - | in-vivo, | BC, | MDA-MB-231 | - | in-vivo, | BC, | MCF7 |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | MCF7 |
| 496- | MF, | Low-Frequency Magnetic Fields (LF-MFs) Inhibit Proliferation by Triggering Apoptosis and Altering Cell Cycle Distribution in Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | ZR-75-1 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 |
| 526- | MF, | Inhibition of Cancer Cell Growth by Exposure to a Specific Time-Varying Electromagnetic Field Involves T-Type Calcium Channels |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Pca, | HeLa | - | vitro+vivo, | Melanoma, | B16-BL6 | - | in-vitro, | Nor, | HEK293 |
| 532- | MF, | A 50 Hz magnetic field influences the viability of breast cancer cells 96 h after exposure |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 |
| 534- | MF, | Effect of extremely low frequency electromagnetic field parameters on the proliferation of human breast cancer |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | Nor, | MCF10 |
| 501- | MF, | Low Intensity and Frequency Pulsed Electromagnetic Fields Selectively Impair Breast Cancer Cell Viability |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 |
| 507- | MF, | Effects of extremely low frequency electromagnetic fields on the tumor cell inhibition and the possible mechanism |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | GP-293 |
| 512- | MF, | Pulsed Electromagnetic Fields (PEMFs) Trigger Cell Death and Senescence in Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | FF95 |
| 7382- | MFrot, | Inhibition of mitochondrial NADH:ubiquinone oxidoreductase by spinning oscillating magnetic fields causes toxicity in cancer cells |
| - | vitro+vivo, | GBM, | NA |
| 2259- | MFrot, | MF, | Method and apparatus for oncomagnetic treatment |
| - | in-vitro, | GBM, | NA |
| 2258- | MFrot, | MF, | EXTH-68. ONCOMAGNETIC TREATMENT SELECTIVELY KILLS GLIOMA CANCER CELLS BY INDUCING OXIDATIVE STRESS AND DNA DAMAGE |
| - | in-vitro, | GBM, | GBM | - | in-vitro, | Nor, | SVGp12 |
| 186- | MFrot, | MF, | Selective induction of rapid cytotoxic effect in glioblastoma cells by oscillating magnetic fields |
| - | in-vitro, | GBM, | GBM | - | in-vitro, | Lung, | NA |
| 187- | MFrot, | MF, | Method for noninvasive whole-body stimulation with spinning oscillating magnetic fields and its safety in mice |
| - | in-vivo, | GBM, | NA |
| 184- | MFrot, | MF, | Rotating Magnetic Fields Inhibit Mitochondrial Respiration, Promote Oxidative Stress and Produce Loss of Mitochondrial Integrity in Cancer Cells |
| - | in-vitro, | GBM, | GBM |
| 205- | MFrot, | MF, | Intermittent F-actin Perturbations by Magnetic Fields Inhibit Breast Cancer Metastasis |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 198- | MFrot, | MF, | Biological effects of rotating magnetic field: A review from 1969 to 2021 |
| - | Review, | Var, | NA |
| 4566- | MFrot, | On the mitochondrial aspect of reactive oxygen species action in external magnetic fields |
| - | Study, | Var, | NA |
| 1891- | MGO, | Methylglyoxal induces mitochondria-dependent apoptosis in sarcoma |
| - | in-vitro, | SCC, | NA |
| 8736- | MGO, | Selective inhibition of mitochondrial respiration and glycolysis in human leukaemic leucocytes by methylglyoxal |
| - | in-vitro, | AML, | NA |
| 8672- | MLT, | Glioblastoma and Melatonin’s Effects: A Narrative Review |
| - | Review, | GBM, | NA |
| 1777- | MLT, | Melatonin as an antioxidant: under promises but over delivers |
| - | Review, | Var, | NA |
| 1778- | MLT, | Melatonin: a well-documented antioxidant with conditional pro-oxidant actions |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 1781- | MLT, | Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial |
| - | Trial, | Lung, | NA |
| 1785- | MLT, | Antitumoral melatonin-loaded nanostructured lipid carriers |
| - | in-vitro, | Var, | NA |
| 8618- | MO, | Lemon Balm Extracts Prevent Breast Cancer Progression In Vitro and In Ovo on Chorioallantoic Membrane Assay |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | A2058 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1110 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid